Performing Simultaneous Cataract Surgery

 

Age-related cataracts can affect both eyes, requiring the endogenic lens to be replaced with an artificial Intraocular Lens (IOL) surgically. Generally, there is a lapse in time between surgeries for each eye, but the surgery can be performed on both eyes on the same day.

A study by Cochrane suggests that there are unlikely to be any large, clinically significant differences between both approaches, though the overall quality was assessed as moderate to very low.

Several advantages to performing the surgery in both eyes simultaneously include fewer hospital visits, faster bilateral vision recovery, and lower procedure costs. 

Risks of simultaneously performing cataract surgery in both eyes consist of developing a postoperative complication in both eyes, and not being able to use the visual acuity from the first operation during the second procedure, since there would only be one. 

The Cochrane review authors noted that the complications generally occurred up to three months post-op, and there were little- to no differences noted between the two methods. Most of the study results were limited by an overall small number of endophthalmitis, postoperative complications, and a lack of specific data, among other variables. 

Thomas Kohnen, MD, PhD, chair of the German Commission for Refractive Surgery (KRC), set up by the German Society of Ophthalmology (DOG), and the Professional Association of German Ophthalmologists (BVA) at the University Clinic Frankfurt, said, “In Germany, there is only very little data on ISBCS because it is barely a topic here. "We have very good medical infrastructure with widespread and prompt ophthalmological care, such that even people living in the countryside do not have to travel great distances or experience long waiting times for a first or second cataract surgery, which is different from many places abroad. The procedure with bilateral operations on the same day is not recommended in the guidelines from our professional societies, [because] any complications that occur postoperatively could potentially entail lengthy legal liability procedures for the surgeons."

In Germany, sequential bilateral cataract surgery is typically performed with two outpatient operations spaced several days (or weeks) apart. Medical, social, or personal reasons can create exceptions to the rule, requiring both eyes to be operated on with a shorter amount of time between each procedure, under general anesthesia in one sitting, or with an overnight gap. 

 

Rohr Eye & Laser Center offers the most advanced technology available to provide personalized and extraordinary care to our patients. Whether your goal is to maintain or improve your natural vision, we are here to help you. Call us at 877-579-0202 to learn more.

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

Radiotherapy Equipment to Last a Lifetime

Medical equipment professionals often debate whether machines are useful past their “expiration” date. Newer radiation therapy equipment is touted to last seven or eight years, noting that it took roughly seven years to design and program before its release, doubling its age instantaneously. Therefore, the technology, software, and knowledge associated with a 14-year-old device is severely outdated. 

However, this thinking is not necessarily true, as there are machines over 20 years old that are operating safely and reliably. In Latin America, a Varian 6X linear accelerator has been treating patients for more than 40 years.

Since 1953, a GE MaximaR 100 X-Ray Device (also known as a Superficial Unit) has been working at a hospital in the United States. For almost 70 years, this unit has helped treat skin cancer patients by producing mild doses of radiation to destroy cancer cells while preserving the surrounding healthy tissue. This machine is still being manufactured for use in dermatology and radiation oncology clinics.

In the Caribbean, a physician at a radiation oncology center said, “Our 2003 Varian 21EX linear accelerator treats over 50 patients per day. It has all the features we want including RapidArc. The 21EX has successfully treated thousands of patients.”

These machines are well-built and are fully capable of lasting longer than seven or eight years. Certain companies purposefully underestimate the life of their linear accelerators to drive sales and increase new model usage. Also, many refurbished linear accelerators use the exact same technology as the current market models. 

Are you looking to purchase a refurbished linear accelerator or have yours repaired? Contact RadParts today.

RadParts is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerator and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost parts and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

 

Particle Accelerators Create Potential Cancer Treatment in Lansing

A Lansing company called Niowave has begun producing actinium-225, a silvery metal isotope that barely exists on Earth, with a superconducting linear accelerator. The reason? This isotope is a promising cancer treatment; however, researchers don’t know its full potential due to the absence of clinical trials. 

Niowave has secured a $5 million deal with Fusion Pharmaceuticals to start production in 2024.  Between Russia, the United States, Germany, and Canada, there are only two curies (unit of measurement for radioactive materials) of actinium-225. Niowave plans on making one curie per week. 

In 2019, the federal government gave Niowave $15 million, and another $13 million last year, to produce molybdenum 99, which is used for medical imaging. Since other countries subsidize its production, making a profit from molybdenum 99 is tricky. 

After working with uranium for years, the federal government determined Niowave could function safely with another highly radioactive element, radium, to create actinium-225. 

Cancer therapy isotopes emit beta particles, which can destroy cancer cells but also kill healthy cells around them. Actinium-225 delivers more targeted alpha particles, which can emit more energy at a shorter distance.

Justin Wilson, an associate professor of chemistry and chemical biology at Cornell University said, “If you can get those alpha particles to the cancer cells, they have the capability of doing more damage but in a more confined region. Which, in theory, could prevent hitting healthy cells that maybe aren’t part of the small metastatic lesion.” 

Eric Burak, chief technical officer at Fusion Pharmaceuticals, states that they are working on formulating three separate drugs that use actinium-225. He said the isotope is “One of the rarest elements in the entire planet, and, with more companies interested in its therapeutic potential, everyone is scrambling for actinium supply.” 

Fusion Pharmaceuticals are investing $5 million to help Niowave create actinium-225 in exchange for a guaranteed share of the end result. 

Niowave’s superconducting linear accelerator has been moved to a concrete room as radium is extremely radioactive. 

_______________________________

RadParts is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerator and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost parts and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/